Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice
Annals of Neurology · 2025
DOI: 10.1002/ana.27149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, 2025. Verfasst von Amira Affaneh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, tau Proteins, Neurons, Bone Morphogenetic Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH-MAD, NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Objective
Many neurodegenerative disorders share a common pathologic feature involving the deposition of abnormal tau protein in the brain (tauopathies). This suggests that there may be some shared pathophysiologic mechanism(s). The largest risk factor for the majority of these disorders is aging, suggesting involvement of the aging process in the shared pathophysiology. We test the hypothesis that an increase in bone morphogenetic protein (BMP) signaling that occurs during aging contributes to the onset and progression of tauopathies.
Methods
Human induced pluripotent stem cell (iPSC)‐derived neurons from patients with Alzheimer's disease (AD) were used to investigate the effects of BMP signaling on tau phosphorylation and release and the mechanisms underlying these effects. Wildtype mice were used to examine effects of BMP signaling in vivo . P301S (PS19) mice were examined for the effects of BMP signaling in a model of tauopathy.
Results
Here, we show that BMP signaling, mediated by non‐canonical p38 signaling, increases tau phosphorylation and release of p‐tau in human iPSC‐derived AD neurons. Further, there is an interaction between BMP signaling and apolipoprotein E4 (ApoE4) that significantly increases tau phosphorylation and release compared with ApoE3 neurons. Inhibiting BMP signaling reduces the changes in tau in the cultured human neurons, and it limits tau pathology and prevents cognitive decline in PS19 mice.
Interpretation
Our study suggests that the age‐related increase in BMP signaling may participate in the onset and progression of tau pathology. Thus, therapeutic interventions that reduce BMP signaling in the aging brain could potentially slow or prevent development of diseases involving tau hyperphosphorylation. ANN NEUROL 2025;97:657–672
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
- Department of Neurosciences, University of New Mexico Health Sciences Center, Albuquerque, NM.
ORCID-Profile: Amira Affaneh, John A Kessler
Förderung
- NIH-MAD
- NIA NIH HHS
- NINDS NIH HHS
- NIAMS NIH HHS
- NIH-NIA
- NIMH NIH HHS
Zitieren
APA
Affaneh, A., Linden, A. K., Tunc-Ozcan, E., Tsai, Y. H., Peng, C. Y., & Kessler, J. A. (2025). Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice. Annals of Neurology. https://doi.org/10.1002/ana.27149
Vancouver
Affaneh A, Linden AK, Tunc-Ozcan E, Tsai YH, Peng CY, Kessler JA. Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice. Annals of Neurology. 2025. doi:10.1002/ana.27149
BibTeX
@article{Affaneh2025,
author = {Affaneh, Amira and Linden, Anne K and Tunc-Ozcan, Elif and Tsai, Yung-Hsu and Peng, Chian-Yu and Kessler, John A},
title = {Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice},
journal = {Annals of Neurology},
year = {2025},
doi = {10.1002/ana.27149}
}
EUVIMED